Evidence map›Paper›PMID 36639805›Full record

ArticleMicrobiome2023

Dynamics of the gut microbiome, IgA response, and plasma metabolome in the development of pediatric celiac disease.

Khyati Girdhar, Yusuf Dogus Dogru, Qian Huang, Yi Yang, Vladimir Tolstikov, Amol Raisingani, Martina Chrudinova, Jaewon Oh, Kristina Kelley, Jonas F Ludvigsson and 4 more

Open access · goldAbstract readVideo-Audio Media
In one paragraph

Article in Microbiome, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Sex-specific cytokine, chemokine, and growth factor signatures in T1D patients and progressors.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Khyati GirdharBoston College Biology Department, Chestnut Hill, MA, 02467, USA.
Yusuf Dogus DogruBoston College Biology Department, Chestnut Hill, MA, 02467, USA.
Qian HuangBoston College Biology Department, Chestnut Hill, MA, 02467, USA.
Yi YangDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, 06510, USA.
Vladimir TolstikovBERG, LLC, Framingham, MA, USA.
Amol RaisinganiBoston College Biology Department, Chestnut Hill, MA, 02467, USA.
Martina ChrudinovaBoston College Biology Department, Chestnut Hill, MA, 02467, USA.
Jaewon OhBoston College Biology Department, Chestnut Hill, MA, 02467, USA.
Kristina KelleyBoston College Biology Department, Chestnut Hill, MA, 02467, USA.
Jonas F LudvigssonDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Michael A KiebishBERG, LLC, Framingham, MA, USA.
Noah W PalmDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, 06510, USA.
Johnny LudvigssonCrown Princess Victoria Children's Hospital, Division of Pediatrics, Department of Biomedical and Clinical Sciences, Linköping University, 58185, Linköping, SE, Sweden.
Emrah AltindisBoston College Biology Department, Chestnut Hill, MA, 02467, USA. altindis@bc.edu.
Boston College · USKarolinska Institutet · SEYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
SPECIAL ASSAY COREP30DK036836 · NIDDK · JOSLIN DIABETES CENTER · PI ROHIT N. KULKARNI · 1986 to 2026
$50.5M
NCATS NIH HHS UL1 TR001863NIDDK NIH HHS P30 DK036836
6 · The paper itself

Abstract

backgroundCeliac disease (CD) is an autoimmune disorder triggered by gluten consumption. Almost all CD patients possess human leukocyte antigen (HLA) DQ2/DQ8 haplotypes; however, only a small subset of individuals carrying these alleles develop CD, indicating the role of environmental factors in CD pathogenesis. The main objective of this study was to determine the contributory role of gut microbiota and microbial metabolites in CD onset. To this end, we obtained fecal samples from a prospective cohort study (ABIS) at ages 2.5 and 5 years. Samples were collected from children who developed CD after the final sample collection (CD progressors) and healthy children matched by age, HLA genotype, breastfeeding duration, and gluten-exposure time (n=15-16). We first used 16S sequencing and immunoglobulin-A sequencing (IgA-seq) using fecal samples obtained from the same children (i) 16 controls and 15 CD progressors at age 2.5 and (ii) 13 controls and 9 CD progressors at age 5. We completed the cytokine profiling, and plasma metabolomics using plasma samples obtained at age 5 (n=7-9). We also determined the effects of one microbiota-derived metabolite, taurodeoxycholic acid (TDCA), on the small intestines and immune cell composition in vivo.

resultsCD progressors have a distinct gut microbiota composition, an increased IgA response, and unique IgA targets compared to healthy subjects. Notably, 26 plasma metabolites, five cytokines, and one chemokine were significantly altered in CD progressors at age 5. Among 26 metabolites, we identified a 2-fold increase in TDCA. TDCA treatment alone caused villous atrophy, increased CD4+ T cells, Natural Killer cells, and two important immunoregulatory proteins, Qa-1 and NKG2D expression on T cells while decreasing T-regulatory cells in intraepithelial lymphocytes (IELs) in C57BL/6J mice.

conclusionsPediatric CD progressors have a distinct gut microbiota composition, plasma metabolome, and cytokine profile before diagnosis. Furthermore, CD progressors have more IgA-coated bacteria and unique targets of IgA in their gut microbiota. TDCA feeding alone stimulates an inflammatory immune response in the small intestines of C57BJ/6 mice and causes villous atrophy, the hallmark of CD. Thus, a microbiota-derived metabolite, TDCA, enriched in CD progressors' plasma, has the potential to drive inflammation in the small intestines and enhance CD pathogenesis. Video Abstract.

Indexed as

Celiac DiseaseGastrointestinal MicrobiomeImmunoglobulin AAnimalsAtrophyChild, PreschoolCytokinesGlutensHumansMetabolomeMiceMice, Inbred C57BLProspective StudiesCytokinesGlutensImmunoglobulin ACeliac diseaseCytokinesGut microbiotaIgA sequencingMetabolitesNKG2DQa-1Taurodeoxycholic acid

Identifiers

PMID36639805
PMCPMC9840338
OpenAlexW4316035595

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.